A new cross-talk between the aryl hydrocarbon receptor and RelB, a member of the NF-κB family

Biochemical Pharmacology

Volumn 77, Issue 4, 2009, Pages 734-745

  Vogel, Christoph F A ^a   Matsumura, Fumio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AhR; IDO; IL 8; NF kappaB RelB; TCDD

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AROMATIC HYDROCARBON RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; TRANSCRIPTION FACTOR RELB;

ARTICLE; CELL DIFFERENTIATION; CELL STRAIN HEPG2; DENDRITIC CELL; DNA RESPONSIVE ELEMENT; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE, TUMOR; HUMANS; LIGANDS; NEOPLASMS; RECEPTOR CROSS-TALK; RECEPTORS, ARYL HYDROCARBON; TETRACHLORODIBENZODIOXIN; TRANSCRIPTION FACTOR RELB;

EID: 59149104324     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.09.036     Document Type: Article

References (98)

1. Gu Y.Z., Hogenesch J.B., and Bradfield C.A. The PAS superfamily: sensors of environmental and developmental signals. Ann Rev Pharmacol Toxicol 40 (2000) 519-561
2. Denison M.S., and Nagy S.R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Ann Rev Pharmacol Toxicol 43 (2003) 309-334
3. Rannug A., Rannug U., Rosenkranz H.S., Winqvist L., Westerholm R., Agurell E., et al. Certain photooxidized derivatives of tryptophan bind with very high affinity to the Ah receptor and are likely to be endogenous signal substances. J Biol Chem 262 (1987) 15422-15427
4. Fritsche E., Schafer C., Calles C., Bernsmann T., Bernshausen T., Wurm M., et al. Lightening up the UV response by identification of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation. Proc Natl Acad Sci USA 104 (2007) 8851-8856
5. Singh S.S., Hord N.G., and Perdew G.H. Characterization of the activated form of the aryl hydrocarbon receptor in the nucleus of HeLa cells in the absence of exogenous ligand. Arch Biochem Biophys 329 (1996) 47-55
6. Ramadoss P., Petrulis J.R., Hollingshead B.D., Kusnadi A., and Perdew G.H. Divergent roles of hepatitis B virus X-associated protein 2 (XAP2) in human versus mouse Ah receptor complexes. Biochemistry 43 (2004) 700-709
7. Petrulis J.R., Hord N.G., and Perdew G.H. Subcellular localization of the aryl hydrocarbon receptor is modulated by the immunophilin homolog hepatitis B virus X-associated protein 2. J Biol Chem 275 (2000) 37448-37453
8. Matsumura F. On the significance of the role of cellular stress response reactions in the toxic actions of dioxin. Biochem Pharmacol 66 (2003) 527-540
9. National Toxicology Program (U.S.), United States. Dept. of Health and Human Services, United States. Public Health Service, National Institutes of Health (U.S.). NTP technical report on the toxicology and carcinogenesis studies of a mixture of 2,3,7,8-tetrachlorodibenzo- rho -dioxin (TCDD) (CAS no. 1746-01-6), 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) (CAS no. 57117-31-4), and 3,3′,4,4′,5-pentachlorobiphenyl (PCB 126) (CAS no. 57465-28-8) in female Harlan Sprague-Dawley rats (gavage studies). Research Triangle Park, N.C.: National Toxicology Program National Institutes of Health Public Health Service U.S. Dept. of Health and Human Services, 2006.
10. Nyska A., Jokinen M.P., Brix A.E., Sells D.M., Wyde M.E., Orzech D., et al. Exocrine pancreatic pathology in female Harlan Sprague-Dawley rats after chronic treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin and dioxin-like compounds. Environ Health Perspect 112 (2004) 903-909
11. Pande K., Moran S.M., and Bradfield C.A. Aspects of dioxin toxicity are mediated by interleukin 1-like cytokines. Mol Pharmacol 67 (2005) 1393-1398
12. Sutter T.R., Guzman K., Dold K.M., and Greenlee W.F. Targets for dioxin: genes for plasminogen activator inhibitor-2 and interleukin-1 beta. Science 254 (1991) 415-418
13. Taylor M.J., Lucier G.W., Mahler J.F., Thompson M., Lockhart A.C., and Clark G.C. Inhibition of acute TCDD toxicity by treatment with anti-tumor necrosis factor antibody or dexamethasone. Toxicol Appl Pharmacol 117 (1992) 126-132
14. Fan F., Yan B., Wood G., Viluksela M., and Rozman K.K. Cytokines (IL-1beta and TNFalpha) in relation to biochemical and immunological effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in rats. Toxicology 116 (1997) 9-16
15. Vogel C., Schuhmacher U.S., Degen G.H., Bolt H.M., Pineau T., and Abel J. Modulation of prostaglandin H synthase-2 mRNA expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin in mice. Arch Biochem Biophys 351 (1998) 265-271
16. Matsumura F., and Vogel C.F. Evidence supporting the hypothesis that one of the main functions of the aryl hydrocarbon receptor is mediation of cell stress responses. Biol Chem 387 (2006) 1189-1194
17. Vogel C.F., Nishimura N., Sciullo E., Wong P., Li W., and Matsumura F. Modulation of the chemokines KC and MCP-1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice. Arch Biochem Biophys 461 (2007) 169-175
18. Vogel C.F., Sciullo E., Li W., Wong P., Lazennec G., and Matsumura F. RelB, a new partner of aryl hydrocarbon receptor-mediated transcription. Mol Endocrinol 21 (2007) 2941-2955
19. Vogel C.F., Sciullo E., Wong P., Kuzmicky P., Kado N., and Matsumura F. Induction of proinflammatory cytokines and C-reactive protein in human macrophage cell line U937 exposed to air pollution particulates. Env Health Perspect 113 (2005) 1536-1541
20. Baggiolini M. Chemokines in pathology and medicine. J Intern Med 250 (2001) 91-104
21. Swanson H.I., and Bradfield C.A. The AH-receptor: genetics, structure and function. Pharmacogenetics 3 (1993) 213-230
22. Poellinger L. Mechanistic aspects-the dioxin (aryl hydrocarbon) receptor. Food Add Contam 17 (2000) 261-266
23. Carlson D.B., and Perdew G.H. A dynamic role for the Ah receptor in cell signaling? Insights from a diverse group of Ah receptor interacting proteins. J Biochem Mol Toxicol 16 (2002) 317-325
24. Hankinson O. Role of coactivators in transcriptional activation by the aryl hydrocarbon receptor. Arch Biochem Biophys 433 (2005) 379-386
25. Ge N.L., and Elferink C.J. A direct interaction between the aryl hydrocarbon receptor and retinoblastoma protein. Linking dioxin signaling to the cell cycle. J Biol Chem 273 (1998) 22708-22713
26. Tian Y., Ke S., Denison M.S., Rabson A.B., and Gallo M.A. Ah receptor and NF-kappaB interactions, a potential mechanism for dioxin toxicity. J Biol Chem 274 (1999) 510-515
27. Klinge C.M., Kaur K., and Swanson H.I. The aryl hydrocarbon receptor interacts with estrogen receptor alpha and orphan receptors COUP-TFI and ERRalpha1. Arch Biochem Biophys 373 (2000) 163-174
28. Ohtake F., Takeyama K., Matsumoto T., Kitagawa H., Yamamoto Y., Nohara K., et al. Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 423 (2003) 545-550
29. Vogel C.F., Sciullo E., and Matsumura F. Involvement of RelB in aryl hydrocarbon receptor-mediated induction of chemokines. Biochem Biophys Res Commun 363 (2007) 722-726
30. Marlowe J.L., Fan Y., Chang X., Peng L., Knudsen E.S., Xia Y., et al. The aryl hydrocarbon receptor binds to E2F1 and inhibits E2F1-induced apoptosis. Mol Biol Cell 19 (2008) 3263-3271
31. Gonzalez F.J., and Fernandez-Salguero P. The aryl hydrocarbon receptor: studies using the AHR-null mice. Drug Metabol Dispos 26 (1998) 1194-1198
32. Lahvis G.P., Pyzalski R.W., Glover E., Pitot H.C., McElwee M.K., and Bradfield C.A. The aryl hydrocarbon receptor is required for developmental closure of the ductus venosus in the neonatal mouse. Mol Pharmacol 67 (2005) 714-720
33. Andreola F., Hayhurst G.P., Luo G., Ferguson S.S., Gonzalez F.J., Goldstein J.A., et al. Mouse liver CYP2C39 is a novel retinoic acid 4-hydroxylase. Its down-regulation offers a molecular basis for liver retinoid accumulation and fibrosis in aryl hydrocarbon receptor-null mice. J Biol Chem 279 (2004) 3434-3438
34. Rodriguez-Sosa M., Elizondo G., Lopez-Duran R.M., Rivera I., Gonzalez F.J., and Vega L. Over-production of IFN-gamma and IL-12 in AhR-null mice. FEBS Lett 579 (2005) 6403-6410
35. Fernandez-Salguero P., Pineau T., Hilbert D.M., McPhail T., Lee S.S., Kimura S., et al. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 268 (1995) 722-726
36. Walisser J.A., Bunger M.K., Glover E., Harstad E.B., and Bradfield C.A. Patent ductus venosus and dioxin resistance in mice harboring a hypomorphic Arnt allele T. J Biol Chem 279 (2004) 16326-16331
37. Quintana F.J., Basso A.S., Iglesias A.H., Korn T., Farez M.F., Bettelli E., et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453 (2008) 65-71
38. Veldhoen M., Hirota K., Westendorf A.M., Buer J., Dumoutier L., Renauld J.C., et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453 (2008) 106-109
39. Baccarelli A., Mocarelli P., Patterson Jr. D.G., Bonzini M., Pesatori A.C., Caporaso N., et al. Immunologic effects of dioxin: new results from Seveso and comparison with other studies. Environ Health Perspect 110 (2002) 1169-1173
40. Funatake C.J., Marshall N.B., and Kerkvliet N.I. 2,3,7,8-Tetrachlorodibenzo-p-dioxin alters the differentiation of alloreactive CD8+ T cells toward a regulatory T cell phenotype by a mechanism that is dependent on aryl hydrocarbon receptor in CD4+ T cells. J Immunotoxicol 5 (2008) 81-91
41. Funatake C.J., Marshall N.B., Steppan L.B., Mourich D.V., and Kerkvliet N.I. Cutting edge: activation of the aryl hydrocarbon receptor by 2,3,7,8-tetrachlorodibenzo-p-dioxin generates a population of CD4+ CD25+ cells with characteristics of regulatory T cells. J Immunol 175 (2005) 4184-4188
42. Vogel C.F., Goth S.R., Dong B., Pessah I.N., and Matsumura F. Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun 375 (2008) 331-335
43. Chen F.E., Huang D.B., Chen Y.Q., and Ghosh G. Crystal structure of p50/p65 heterodimer of transcription factor NF-kappaB bound to DNA. Nature 391 (1998) 410-413
44. Kunsch C., Ruben S.M., and Rosen C.A. Selection of optimal kappa B/Rel DNA-binding motifs: interaction of both subunits of NF-kappa B with DNA is required for transcriptional activation. Mol Cell Biol 12 (1992) 4412-4421
45. Dejardin E. The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol 72 (2006) 1161-1179
46. Dejardin E., Droin N.M., Delhase M., Haas E., Cao Y., Makris C., et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 17 (2002) 525-535
47. Bonizzi G., Bebien M., Otero D.C., Johnson-Vroom K.E., Cao Y., Vu D., et al. Activation of IK{cyrillic}K{cyrillic}alpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO 23 (2004) 4202-4210
48. Calvano S.E., Xiao W., Richards D.R., Felciano R.M., Baker H.V., Cho R.J., et al. A network-based analysis of systemic inflammation in humans. Nature 437 (2005) 1032-1037
49. Basak S., and Hoffmann A. Crosstalk via the NF-kappaB signaling system. Cytokine Growth Factor Rev 19 (2008) 187-197
50. Basak S., Kim H., Kearns J.D., Tergaonkar V., O'Dea E., Werner S.L., et al. A fourth IkappaB protein within the NF-kappaB signaling module. Cell 128 (2007) 369-381
51. Weih F., Carrasco D., Durham S.K., Barton D.S., Rizzo C.A., Ryseck R.P., et al. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell 80 (1995) 331-340
52. Burkly L., Hession C., Ogata L., Reilly C., Marconi L.A., Olson D., et al. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 373 (1995) 531-536
53. Cejas P.J., Carlson L.M., Kolonias D., Zhang J., Lindner I., Billadeau D.D., et al. Regulation of RelB expression during the initiation of dendritic cell differentiation. Mol Cell Biol 25 (2005) 7900-7916
54. Munn D.H., Sharma M.D., Lee J.R., Jhaver K.G., Johnson T.S., Keskin D.B., et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297 (2002) 1867-1870
55. Tas S.W., Vervoordeldonk M.J., Hajji N., Schuitemaker J.H., van der Sluijs K.F., May M.J., et al. Noncanonical NF-kappaB signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation. Blood 110 (2007) 1540-1549
56. Jost P.J., and Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 109 (2007) 2700-2707
57. Xiao G., Rabson A.B., Young W., Qing G., and Qu Z. Alternative pathways of NF-kappaB activation: a double-edged sword in health and disease. Cytokine Growth Factor Rev 17 (2006) 281-293
58. Zhang B., Wang Z., Li T., Tsitsikov E.N., and Ding H.F. NF-kappaB2 mutation targets TRAF1 to induce lymphomagenesis. Blood 110 (2007) 743-751
59. Vogel C.F., Li W., Sciullo E., Newman J., Hammock B., Reader J.R., et al. Pathogenesis of aryl hydrocarbon receptor-mediated development of lymphoma is associated with increased cyclooxygenase-2 expression. Am J Pathol 171 (2007) 1538-1548
60. Wang X., Belguise K., Kersual N., Kirsch K.H., Mineva N.D., Galtier F., et al. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol 9 (2007) 470-478
61. Sovak M.A., Bellas R.E., Kim D.W., Zanieski G.J., Rogers A.E., Traish A.M., et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100 (1997) 2952-2960
62. Van Laere S.J., Van der Auwera I., Van den Eynden G.G., van Dam P., Van Marck E.A., Vermeulen P.B., et al. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. Br J Cancer 97 (2007) 659-669
63. Lessard L., Begin L.R., Gleave M.E., Mes-Masson A.M., and Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 93 (2005) 1019-1023
64. Van Laere S.J., Van der Auwera I., Van den Eynden G.G., Elst H.J., Weyler J., Harris A.L., et al. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res 12 (2006) 3249-3256
65. Zhang J., Warren M.A., Shoemaker S.F., and Ip M.M. NFkappaB1/p50 is not required for tumor necrosis factor-stimulated growth of primary mammary epithelial cells: implications for NFkappaB2/p52 and RelB. Endocrinol 148 (2007) 268-278
66. Singhal R., Shankar K., Badger T.M., and Ronis M.J. Estrogenic status modulates aryl hydrocarbon receptor-mediated hepatic gene expression and carcinogenicity. Carcinogenesis 29 (2008) 227-236
67. Schlezinger J.J., Liu D., Farago M., Seldin D.C., Belguise K., Sonenshein G.E., et al. A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis. Biol Chem 387 (2006) 1175-1187
68. Ali S., and Lazennec G. Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev 26 (2007) 401-420
69. Freund A., Jolivel V., Durand S., Kersual N., Chalbos D., Chavey C., et al. Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene 23 (2004) 6105-6114
70. Bieche I., Chavey C., Andrieu C., Busson M., Vacher S., Le Corre L., et al. CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr Relat Cancer 14 (2007) 1039-1052
71. Wu K., Katiyar S., Li A., Liu M., Ju X., Popov V.M., et al. Dachshund inhibits oncogene-induced breast cancer cellular migration and invasion through suppression of interleukin-8. Proc Natl Acad Sci USA 105 (2008) 6924-6929
72. Thatcher T.H., Maggirwar S.B., Baglole C.J., Lakatos H.F., Gasiewicz T.A., Phipps R.P., et al. Aryl hydrocarbon receptor-deficient mice develop heightened inflammatory responses to cigarette smoke and endotoxin associated with rapid loss of the nuclear factor-kappaB component RelB. Am J Pathol 170 (2007) 855-864
73. Iourgenko V., Zhang W., Mickanin C., Daly I., Jiang C., Hexham J.M., et al. Identification of a family of cAMP response element-binding protein coactivators by genome-scale functional analysis in mammalian cells. Proc Natl Acad Sci USA 100 (2003) 12147-12152
74. Oesch-Bartlomowicz B., Huelster A., Wiss O., Antoniou-Lipfert P., Dietrich C., Arand M., et al. Aryl hydrocarbon receptor activation by cAMP vs. dioxin: divergent signaling pathways. Proc Natl Acad Sci USA 102 (2005) 9218-9223
75. de Oliveira S.K., Hoffmeister M., Gambaryan S., Müller-Esterl W., Guimaraes J.A., and Smolenski A.P. Phosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor. J Biol Chem. 282 (2007) 13656-13663
76. Bunger M.K., Glover E., Moran S.M., Walisser J.A., Lahvis G.P., Hsu E.L., et al. Abnormal liver development and resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity in mice carrying a mutation in the DNA binding domain of the aryl hydrocarbon receptor. Toxicol Sci (2008)
77. Li W., Vogel C.F., Fujiyoshi P., and Matsumura F. Development of a human adipocyte model derived from human mesenchymal stem cells (hMSC) as a tool for toxicological studies on the action of TCDD. Biol Chem 389 (2008) 169-177
78. Vogel C., Boerboom A.M., Baechle C., El-Bahay C., Kahl R., Degen G.H., et al. Regulation of prostaglandin endoperoxide H synthase-2 induction by dioxin in rat hepatocytes: possible c-Src-mediated pathway. Carcinogenesis 21 (2000) 2267-2274
79. Baglole CJ, Maggirwar SB, Gasiewicz TA, Thatcher TH, Phipps RP, Sime PJ. The aryl hydrocarbon receptor attenuates tobacco smoke induced cyclooxygenase-2 and prostaglandin production in lung fibroblasts through regulation of the NF-kappa B family member RELB. J Biol Chem 2008 Aug 12 [Epub ahead of print].
80. Martey C.A., Baglole C.J., Gasiewicz T.A., Sime P.J., and Phipps R.P. The aryl hydrocarbon receptor is a regulator of cigarette smoke induction of the cyclooxygenase and prostaglandin pathways in human lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 289 Sep (3) (2005) L391-L399
81. Lee J.A., Hwang J.A., Sung H.N., Jeon C.H., Gill B.C., Youn H.J., et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin modulates functional differentiation of mouse bone marrow-derived dendritic cells downregulation of RelB by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Lett 173 (2007) 31-40
82. Kerkvliet N.I. Recent advances in understanding the mechanisms of TCDD immunotoxicity. Int Immunopharmacol 2 (2002) 277-291
83. Hauben E., Gregori S., Draghici E., Migliavacca B., Olivieri S., Woisetschlager M., et al. Activation of the aryl hydrocarbon receptor promotes allograft specific tolerance through direct- and DC-mediated effects on regulatory T cells. Blood (2008)
84. Steinman R.M., and Nussenzweig M.C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 99 (2002) 351-358
85. Mahnke K., Ring S., Johnson T.S., Schallenberg S., Schonfeld K., Storn V., et al. Induction of immunosuppressive functions of dendritic cells in vivo by CD4+CD25+ regulatory T cells: role of B7-H3 expression and antigen presentation. Euro J Immunol 37 (2007) 2117-2126
86. Vorderstrasse B.A., Dearstyne E.A., and Kerkvliet N.I. Influence of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the antigen-presenting activity of dendritic cells. Toxicol Sci 72 (2003) 103-112
87. Vorderstrasse B.A., and Kerkvliet N.I. 2,3,7,8-Tetrachlorodibenzo-p-dioxin affects the number and function of murine splenic dendritic cells and their expression of accessory molecules. Toxicol Appl Pharmacol 171 (2001) 117-125
88. Ruby C.E., Leid M., and Kerkvliet N.I. 2,3,7,8-Tetrachlorodibenzo-p-dioxin suppresses tumor necrosis factor-alpha and anti-CD40-induced activation of NF-kappaB/Rel in dendritic cells: p50 homodimer activation is not affected. Mol Pharmacol 62 (2002) 722-728
89. Lawrence B.P., Denison M.S., Novak H., Vorderstrasse B.A., Harrer N., Neruda W., Reichel C., and Woisetschläger M. Activation of the aryl hydrocarbon receptor is essential for mediating the anti-inflammatory effects of a novel low-molecular-weight compound. Blood 112 Aug (4) (2008) 1158-1165
90. Jensen B.A., Leeman R.J., Schlezinger J.J., and Sherr D.H. Aryl hydrocarbon receptor (AhR) agonists suppress interleukin-6 expression by bone marrow stromal cells: an immunotoxicology study. Environ Health 2 1 (Dec 16 2003) 16
91. Kim D.W., Gazourian L., Quadri S.A., Romieu-Mourez R., Sherr D.H., and Sonenshein G.E. The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells. Oncogene 48 (2000) 5498-5506
92. Xia Y., Pauza M.E., Feng L., and Lo D. RelB regulation of chemokine expression modulates local inflammation. Am J Pathol 151 (1997) 375-387
93. Pereira S.G., and Oakley F. Nuclear factor-kappaB1: regulation and function. Int J Biochem Cell Biol 40 (2008) 1425-1430
94. Lawrence T., Bebien M., Liu G.Y., Nizet V., and Karin M. IK{cyrillic}K{cyrillic}alpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 434 (2005) 1138-1143
95. Matos P., and Jordan P. Rac1, but not Rac1B, stimulates RelB-mediated gene transcription in colorectal cancer cells. J Biol Chem 281 (2006) 13724-13732
96. Josson S., Xu Y., Fang F., Dhar S.K., St Clair D.K., and St Clair W.H. RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Oncogene 25 (2006) 1554-1559
97. Lwin T., Hazlehurst L.A., Li Z., Dessureault S., Sotomayor E., Moscinski L.C., et al. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia 21 (2007) 1521-1531
98. Hockings J.K., Thorne P.A., Kemp M.Q., Morgan S.S., Selmin O., and Romagnolo D.F. The ligand status of the aromatic hydrocarbon receptor modulates transcriptional activation of BRCA-1 promoter by estrogen. Cancer Res 66 (2006) 2224-2232